Kornimate/medical-research-clean huggingface dataset:
rosacea treatment using non-thermal (cold) atmospheric plasma device

Conditions: Rosacea, Papulopustular

Summary: 10-13 patients will be enrolled to receive split face treatment: the control side will be treated with metronidazole cream, the intervention side will be treated with a cold atmospheric plasma device


Eligibility criteria:
inclusion criteria: * papulopustular rosacea of the cheeks * ability to complete six weeks of twice-weekly treatments exclusion criteria: * substantial asymmetry of disease distribution * previous failure of topical ivermectin treatment * presence of any other facial dermatoses * presence of any photosensitizing disorders * systemic tetracycline, systemic or topical ivermectin treatment within 6 weeks of start date * current or within prior 3 months treatment with systemic immune-suppressive medication
hypotensive effects of conventional dairy products: role of arterial stiffness

Conditions: Prehypertension; Stage-1 Hypertension

Summary: elevated systolic blood pressure is by far the largest single contributor to cardiovascular risks in middle-aged and older adults. lifestyle modifications, including dietary modifications, are the first line approach for treating and preventing hypertension. the general aim of the proposed study is to address the efficacy of conventional dairy products as part of the normal routine diet for lowing arterial blood pressure in middle-aged and older adults with elevated blood pressure. the investigators hypothesize that the dietary intervention including dairy products will induce significant decreases in arterial blood pressure in this population. a secondary aim will be to test the hypothesis that these reductions in systolic blood pressure will be associated with increases in arterial stiffness/compliance and endothelial vasodilatory function.


Eligibility criteria:
inclusion criteria: * prehypertension or stage-1 hypertension exclusion criteria: * consume \> 3 servings of dairy or fruit per day * strenuous physical activity \> 3 time per week * lactose intolerance, pregnancy, lactation, and/or alcohol abuse * taking cardiovascular-acting drugs * overt cardiovascular disease, metabolic disease, gi disorders and/or renal disease
distant delivery of a mindfulness-based intervention for people affected by parkinson's disease

Conditions: Parkinson's Disease

Summary: psychological difficulties, especially depression and anxiety are the most prevalent non-motor symptoms in parkinson's disease (pd). pharmacological treatments are not as effective in pd. mindfulness courses have received increased popularity and recognition as an effective way to manage emotional states, and there is ever growing findings of the effectiveness of mindfulness courses for people with long-term medical conditions. two small pilot studies have indicated that mindfulness courses can be helpful for people with pd in improving symptoms of depression, language functioning and motor symptoms. the investigators propose to deliver these courses remotely, through skype video conferences, to make it more accessible for people with mobility limitations and people who live in rural areas.

this study will employ a mixed-methods design, with an experimental randomised control trial followed by a qualitative design. sixty participants will be randomly assigned to the 8-week mindfulness course (n=30) or a wait-list control group (n=30). block randomisation will be used and the randomisation scheme will be generated using the randomisation.com website. one-hour sessions will be delivered to groups of 5 people using skype video-conferencing. as this is a pilot study analyses will largely be descriptive. further, inferential analyses using mixed modelling will be conducted by intention-to-treat. at the end of the intervention, the investigators will interview the participants of the mindfulness group about their experiences of the course.

Eligibility criteria:
inclusion criteria: * be diagnosed with pd according to pd brain bank criteria by a neurologist or geriatrician * have a computer and internet access at home, since the course will be delivered via skype * be able to communicate in english fluently * be stabilised on mood altering medication and/or parkinson's medication for a month exclusion criteria: * have severe cognitive impairment that would make participation in the mindfulness sessions and home practice of mindful meditation problematic or distressing. this will be assessed using the telephone interview for cognitive status-modified (tics-m, brandt et al., 1993). * have severe psychiatric conditions (e.g. psychosis, drug/ alcohol addiction) that can potentially risk failure in the treatment or limit participation in the course * have severe hearing impairment * are currently participating in other psychological therapies * have prior formal training in mindfulness methods or current meditation practice

Keywords: pd parkinson's
a comparison of magnetic resonance imaging in persons with heart failure to health, aged matched controls

Conditions: Heart Failure

Summary: the purpose of this study is to examine the relation between the structural brain changes associated with heart failure, neurocognitive performance, and how these changes impact self-care behaviors.

the purpose of this study is use neuroimaging techniques to better understand the underlying structural brain changes and physiological mechanisms that guide the thinking and decision making processes required for people with heart failure. the study will compare how the underlying brain structures and circulation are similar to or different in persons with heart failure to healthy, aged matched controls using special neuroimaging procedures.

Eligibility criteria:
inclusion criteria: participants with heart failure: * speak and understand english * live independently within a 60 mile radius of atlanta * montreal cognitive assessment (moca) score of less than or equal to 24 * documented medical diagnosis of new york heart association (nyha) class ii or iii systolic * left ventricular ejection fraction (lvef) greater than or equal to 10% that is documented within the last year by echocardiogram, cardiac catheterization ventriculography, or radionuclide ventriculography * receiving medication therapy for heart failure (hf) according to american college of cardiology (acc) american heart recommendation guidelines for at least 8 weeks prior to study enrollment healthy controls * speak and understand english * live independently within a 60 mile radius of atlanta exclusion criteria: participants with heart failure: * new york heart association (nyha) class i or iv * change in heart failure (hf) therapy within 6 months * worsening of heart failure (hf) symptoms within last 5 days * unstable angina * renal insufficiency (serum creatinine greater than 3.o mg/dl) * hospitalized within the last 30-days * diagnosed with any neurological disorder that may interfere with cognitive function * beck depression inventory ii (bdi-ii) score greater than 25 * claustrophobia * implanted devices such as internal cardiac defibrillator or pacemaker * carrying non-removable objects * stents * body weight more than 120 kg healthy controls * taking prescription medications * cardiovascular disease; * cerebrovascular disease * neurological disease * respiratory disease * claustrophobia * any implanted metal objects not considered safe or appropriate for the mri environment.

Keywords: cardiomyopathy magnetic resonance imaging (mri)
cryoablation in patients with atrial flutter

Conditions: Atrial Flutter

Summary: the investigators hypothesized that revealing the incidence of af following rfa of the cti and cryoablation pvi reduces incidence of af following rfa of the cti.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * ecg documented paroxysmal or persistent afl * no prior documented history of af * patient undergoing rfa of the cti for afl. * no indication (other than afl) for continued anticoagulation with warfarin. * no existing implantable cardiac device (pacemaker, defibrillator, cardiac resynchronization therapy device) * availability of an analog phone line. exclusion criteria: * a history of atrial fibrillation * previous af ablation procedure * congestive heart failure * left ventricle ejection fraction less than 35% * unwillingness to participate
transpalpebral micro-current electrical stimulation for the treatment of dry age-related macular degeneration

Conditions: Age-Related (Dry) Macular Degeneration

Summary: assess the effectiveness of externally applied micro current electrical stimulation on improving the etdrs visual acuity in subjects with vision loss from dry age-related macular degeneration (amd)

micro-current electrical stimulation will be used to treat /each eye in a group of subjects with dry amd. 60 subjects will be randomly divided into two groups. a ratio of 1:3 will be maintained between control and the experimental groups. in the treatment group, subjects will undergo a treatment session to the enrolled eyes daily for three days during week 1, followed by a single treatment session during weeks 2, 14 and 26 with the nova oculus device. a second group of subjects will act as the control group. this group will undergo sham treatment at the same treatment intervals with a non-functional nova oculus device. etdrs visual acuity will be performed on all subjects at enrollment prior to each treatment and at four weeks from enrollment. the effect of treatments with the nova oculus device compared to sham treatment on the etdrs visual acuity of subjects with dry amd will be determined.

Eligibility criteria:
inclusion criteria: * fifty years of age or older * male or female * best-corrected vision 20/50 to 20/200 for each enrolled eye * confirmed diagnosis of dry amd * vision loss attributable to dry amd * subjects must be highly motivated, alert, oriented, mentally competent and able to understand and comply with the requirements of the study, abide by the restrictions, return for all required visits, and provide voluntary informed consent exclusion criteria: * any visually significant retinal pathology other than dry amd * previous intravitreal injection * seizure disorders * previous vitreo-retinal surgery. (erm, ppv, rd etc) * dense cataract * eyelid pathology at the treatment sites * glaucoma patients with a visual field mean defect of greater than 10db on humphrey visual field testing * glasses are up to date (prescription \<1 year old) * any prior electrical micro-stimulation treatment to the eyes * poor general health * active cancer * life expectancy less than 12 months * non-ambulatory * not considered suitable for participation for any other reason
end nicotine dependence clinic

Conditions: Smoking Cessation

Summary: the purpose of this research is to study a smoking cessation program for adult smokers in northeast ohio. the study will also look at how different people respond to the program.

objective 1: to examine the feasibility of conducting an evidence-based, cognitive behavioral therapy (cbt) for tobacco cessation delivered in multiple formats. participants will have the opportunity to receive a cbt-based tobacco intervention delivered several possible formats (face-to-face, telephone, video-counseling) based on availability and participant preferences. study participants will be exposed to cognitive-behavioral cessation and relapse prevention strategies, and discuss barriers to cessation, previous quit attempts, risky situations, and benefits observed after quitting. participants may also complete exercises designed to assist cessation attempts (e.g., mental and behavioral coping skills, cognitive reframing exercise, health benefits of cessation; and no-smoking behavioral contracts). as supplemental treatment, participants may have the option to receive up to 8 weeks of nicotine replacement therapy and text-messaging support. objective 2: to examine the rates of smoking abstinence across intervention formats. investigators will attempt to follow-up with participants for a 6-months after program completion. investigators will assess point prevalence abstinence for each intervention delivery method. objective 3: to assess individual difference variables that influence outcomes. investigators will examine individual-difference predictors of outcomes, such as readiness to quit, social support, distress, and environmental factors.

Eligibility criteria:
inclusion criteria: * current smokers who would like help quitting (≥ 5 cigarettes per day and/or have a breath carbon monoxide (co) reading of ≥ 8 ppm) * able to speak and read english * able to engage using at least one of the intervention formats. exclusion criteria: * enrollment in another cessation program * do not speak and read english * do not have access to at least one intervention format * have contraindications for nrt * do not have contact information (e.g., address, telephone number) * are in treatment for substance abuse (e.g., illicit drugs, alcohol abuse) * they endorse active addiction to another substance (e.g., illicit drugs or alcohol). * people who self-report having a severe mental illness

Keywords: nicotine dependence applied behavioral research
safety and efficacy of ledipasvir/sofosbuvir fixed-dose combination ± ribavirin for the treatment of hcv (ion-3)

Conditions: Chronic Hepatitis C Virus

Summary: this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (ldv/sof) fixed-dose combination (fdc) with or without ribavirin (rbv) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 hcv infection.


Eligibility criteria:
inclusion criteria: * age \> 18, with chronic genotype 1 hcv infection * hcv treatment-naive * hcv rna \> 10,000 iu/ml at screening * screening laboratory values within defined thresholds * use of two effective contraception methods if female of childbearing potential or sexually active male exclusion criteria: * pregnant or nursing female or male with pregnant female partner * presence of cirrhosis * coinfection with hiv or hepatitis b virus (hbv) * current or prior history of clinical hepatic decompensation * chronic use of systemic immunosuppressive agents * history of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

Keywords: hcv genotype 1 (gt-1) hcv sustained virologic response direct acting antiviral combination therapy gs-7977 gs-5885 ribavirin open label sofosbuvir additional relevant mesh terms: hepatitis hepatitis, chronic hepatitis c hepatitis c, chronic liver diseases digestive system diseases hepatitis, viral, human virus diseases enterovirus infections picornaviridae infections rna virus infections flaviviridae infections antiviral agents anti-infective agents therapeutic uses pharmacologic actions antimetabolites molecular mechanisms of pharmacological action
ed physical therapy for chronic low back pain

Conditions: Low Back Pain

Summary: emergency department (ed)-initiated physical therapy is a rapidly growing resource and represents a promising treatment approach to low back pain. this clinical trial will evaluate an innovative model of an emergency department "embedded" physical therapist to treat patients with chronic low back pain, with a focus on improving patient functioning and reducing opioid use.

this trial is ancillary to an ongoing single-center physician-randomized trial of an embedded physical therapy intervention versus usual care in ed patients with acute low back pain (need-pt, nct04921449), comparing a primary outcome of pain-related functioning and a secondary outcome of opioid use at three months. the main trial aims to enroll up to 360 participants with acute low back pain, defined as ≤ 30 days in duration and no history of lumber surgery or chronic low back pain. using the same procedures and physician-randomization assignments as the main trial, this ancillary trial will enroll an additional 200 participants with chronic low back pain (i.e. non-acute low back pain) in order to obtain initial point estimates for the outcomes of interest and assess participant enrollment and retention rates in this population. the ancillary trial's sample size of 200 participants is an estimate of patient accrual over the anticipated remaining duration of the main trial (i.e., there is not a separate power calculation for this ancillary trial given its exploratory nature), and the actual number accrued may differ depending on the main trial's actual end date.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * low back pain (originating between 12th rib and buttocks) * evaluated by a physician randomized to either study arm * evaluated when ed physical therapy is available (e.g., mon-fri, 8am-4pm) * likely to be discharged home (based on physician assessment) * ability to complete follow-up data collection electronically or by telephone * english-speaking exclusion criteria: * enrollment in the main trial (need-pt, nct04921449) * serious red-flag signs/symptoms (bladder/bowel incontinence, saddle anesthesia, debilitating motor weakness) * obvious non-musculoskeletal etiology for low back pain (e.g., shingles, kidney stone) * other concomitant injuries or pain (e.g., closed head injury, shoulder pain) * unable to ambulate at baseline * known pregnancy, under police custody, unable to consent

Keywords: low back pain chronic physical therapy emergency department functioning disability opioid
hpv infection and cervical neoplasm in women with inflammatory bowel disease: a cross-sectional study

Conditions: HPV-Related Cervical Carcinoma; Inflammatory Bowel Diseases; Cervical Neoplasm

Summary: the associations between female inflammatory bowel disease (ibd) patients and human papilloma virus (hpv) infection and cervical neoplasia (dysplasia or cancer) were unclear. especially there was no data for chinese ibd population. so we investigated the incidence and risk factors of hpv infection and cervical neoplasia (dysplasia or cancer) in female ibd patient.


Eligibility criteria:
inclusion criteria: 1. between 20-60 years old; 2. patients diagnosed as ibd according to previously established international criteria exclusion criteria: 1. patients refuse to participating
low-intensity focused ultrasound (lifu) neuromodulation

Conditions: Alzheimer Disease

Summary: this study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of lifu for neuromodulation in patients with mild cognitive impairment ( mci) due to alzheimer's disease.

the primary objective is to evaluate the safety, feasibility and tolerability of lifu as an adjunct neuromodulatory treatment for mci due to ad

Eligibility criteria:
inclusion criteria: * males and non-pregnant females, aged 45-85 years * able and willing to give informed consent * must meet the clinical criteria for mci due to alzheimer's disease * if receiving concurrent treatment with an achei and/or memantine, has been on a stable dose for at least 45 days * able to communicate sensations during the lifu procedure exclusion criteria: * unable to undergo mr-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small spaces (have claustrophobia). * participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain. * participants with a history of seizure disorder. * participants with clinically significant chronic pulmonary disorders e.g., severe emphysema, pulmonary vasculitis, or other causes of reduced pulmonary vascular cross-sectional area. * participant does not speak english * participant is pregnant or planning to be pregnant
effects of aerobic exercise detraining

Conditions: Motor Activity; Body Weight; Obesity

Summary: the proposed study seeks to better understand the role of body weight, energy expenditure, and energy intake as mechanisms of body weight gain during detraining following aerobic exercise. it is hypothesized that participants in the higher dose exercise group will have greater body weight gain compared to the lower exercise dose and control group from wk 24 to wk 76 follow-up.

eligibility criteria include having successfully completed the main e-mechanic study, be willing to archive blood samples and not being currently enrolled in another study that may effect body, energy intake or energy expenditure. the investigators will measure body weight, waist/hip circumference, blood pressure, body composition, physical activity, questionnaire about appetite/food intake and physical fitness.

Eligibility criteria:
inclusion criteria: * completed the e-mechanic study * be willing to archive blood samples * not participating in a study that would alter body weight, energy intake, or energy expenditure.

Keywords: physical inactivity aerobic exercise detraining body weight energy expenditure metabolic syndrome
clinico-pathologic-genetic-imaging study of neurodegenerative and related disorders

Conditions: PSP; CBD; PCA; LPA; Semantic Dementia; Semantic Aphasia; Behavioral Variant of Frontotemporal Dementia; FTD; PPA; Apraxia of Speech; MSA - Multiple System Atrophy; Parkinson Disease

Summary: the investigators aim to learn more about symptoms suggestive of a neurodegenerative process.

the investigators will recruit participants with symptoms suggestive of a neurodegenerative and/or related disease. participants could be evaluated on a yearly basis, undergoing a baseline visit and possible follow-up evaluations with an interval of one year. at each visit, participants could undergo any combination of the following based on their symptoms and complaints: a neurological assessment, a speech/language assessment, a neuropsychometric assessment, an mri, an fdg pet/ct scan, a pib pet/ct scan, a tau pet/ct scan and/or a c-11 er176 pet/ct scan. all participants will be asked to provide a blood sample to allow for future genetic studies.

Eligibility criteria:
inclusion criteria: * all participants will be over the age of 21 * have symptoms suggestive of a neurodegenerative and/or related disorder exclusion criteria: * participants will be excluded if they have any concurrent illnesses that could account for all of their symptoms, such as traumatic brain injury, encephalitis, strokes or developmental syndromes * women that are pregnant or post-partum and breast-feeding will be excluded * participants will be excluded if they have any of the following genetic conditions which can increase the chance of cancer: cowden disease, lynch syndrome, hypogammaglobulinemia, wiskott-aldrich syndrome and down's syndrome * participants will be excluded if mri is contraindicated (metal in head, cardiac pace maker, etc), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma, intracranial neoplasm or large cortical infarcts) * participants will be excluded if they are medically unstable or are on medications that might affect brain structure or metabolism (e.g. chemotherapy)